[Molecular signatures of breast cancer: What clinical utility?].
The role of molecular signatures in the adjuvant management of breast cancer remains a debated topic. Discussions should take into account the level of scientific validation, the impact on practice, the expected benefits and financing issues. This article presents the key points for a rational use of commercial molecular signatures.